All Oncology News

A biologics license application (BLA) has been submitted for ABP-215, a biosimilar version of bevacizumab (Avastin), based on data from analytical, pharmacokinetic, clinical data, pharmacology, and toxicology data, according to a statement from Amgen and Allergan, the developers of the biosimilar.

Dual HER2-directed therapy has demonstrated promising efficacy as a treatment approach for patients with breast cancer. Still, there remains a need for further research pertaining to therapies for HER2-positive patients who do do not meet the current criteria for this neoadjuvant regimen.

Pivotal clinical trial findings from the past year will likely have a game-changing effect on the multiple myeloma landscape, according to Rafael Fonseca, MD. Moreover, he adds, oncologists may be looking at a future where the number of drugs in a single regimen continues to grow in an effort to further improve outcomes.

Nivolumab (Opdivo) may be the only checkpoint inhibitor that is approved by the FDA as a treatment of patients with Hodgkin lymphoma, but other immunotherapies—alone and in combination with other novel agents—are emerging in other indications.

The European Commission approved palbociclib (Ibrance) for use in patients with HR-positive, HER2-negative locally advanced or metastatic breast cancer, either in combination with an aromatase inhibitor in the frontline setting or combined with fulvestrant after progression on endocrine therapy.